Filtered By:
Condition: Cough

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 318 results found since Jan 2013.

Isolated Acute Cerebrovascular Involvement in COVID-19 without Fever and Respiratory Symptoms: An Indian Perspective
CONCLUSION: Isolated cerebrovascular involvement can be a presentation of COVID-19.Stroke severity and mortality is higher in COVID-19 with young strokes being no exemption. Development of fever was associated with clinical worsening. COVID-19 pandemic is far from over in India, such atypical presentations need to be recognized early and warrant stringent diagnostic protocols.PMID:34227776
Source: Journal of the Association of Physicians of India - July 6, 2021 Category: General Medicine Authors: P V Sripadma Rajendra Singh Jain Arvind Vyas Bhawna Sharma Trilochan Srivastava Sourabh Murarka Piyush Saavaliya Jitesh Agrawal Kaavya Rao Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Demyelination as a result of an immune response in patients with COVID-19
AbstractThe coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2), that already appeared as a global pandemic. Presentation of the disease often includes upper respiratory symptoms like dry cough, dyspnea, chest pain, and rhinorrhea that can develop to respiratory failure, needing intubation. Furthermore, the occurrence of acute and subacute neurological manifestations such as stroke, encephalitis, headache, and seizures are frequently stated in patients with COVID-19. One of the reported neurological complications of severe COVID-19 is the demolition of the my...
Source: Acta Neurologica Belgica - May 2, 2021 Category: Neurology Source Type: research

Comprehensive Respiratory Muscle Training Improves Pulmonary Function and Respiratory Muscle Strength in Acute Stroke Patients
Conclusion: Four weeks of comprehensive RMT in patients with acute stroke resulted in significantly greater improvements in both pulmonary function and respiratory muscle strength than SR. Therefore, RMT has the potential to reduce post-stroke respiratory complications.
Source: Journal of Cardiopulmonary Rehabilitation - April 30, 2021 Category: Rehabilitation Tags: Cardiac Rehabilitation Source Type: research

First of its kind study links wildfire smoke to skin disease
(University of California - San Francisco) Wildfire smoke can trigger a host of respiratory and cardiovascular symptoms, ranging from runny nose and cough to a potentially life-threatening heart attack or stroke. A new study suggests that the dangers posed by wildfire smoke may also extend to the largest organ in the human body, and our first line of defense against outside threat: the skin.
Source: EurekAlert! - Cancer - April 21, 2021 Category: Cancer & Oncology Source Type: news

COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin
A 31-year-old sexually active, non-smoker female with a past medical history of spina-bifida and idiopathic thoracolumbar scoliosis status post hardware spinal fusion surgery five years ago presented with a one-day history of severe holocranial headaches associated with nausea and visual changes. A thorough neurological examination was intact. She complained of mild cough as well. She had a positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR assay. A comprehensive drug screen including amphetamines, cocaine, nicotine, alcohol, and ecstasy as well as a pregnancy test were negative; coagulation profile was within normal limits.
Source: Journal of Stroke and Cerebrovascular Diseases - April 12, 2021 Category: Neurology Authors: Tarab Mansoor, Ali A. Alsarah, Hossein Mousavi, Javed Elyias, Tarun Girotra, Omar Hussein Tags: Case Report Source Type: research